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ABSTRACT 
 
Objective: The objective of this selective evidence-based medicine (EBM) review is to  
determine whether or not Tribulus terrestris is effective at increasing sexual desire in adult 
women suffering from hypoactive sexual desire disorder (HSDD). 
 
Study Design: Review of three randomized controlled trials published in 2014, 2016, and 2017; 
selection was based on their relevance to the clinical question and on their patient-oriented 
outcomes. 
 
Data Sources: Three peer-reviewed primary studies comparing the use of Tribulus terrestris to 
placebo in the treatment of HSDD were found on PubMed. 
 
Outcome(s) Measured: For each trial, patients were divided into either Tribulus terrestris 
treatment or placebo treatment groups. Trials assessed female sexual function index (FSFI) and 
sexual quotient female (QS-F) questionnaire score improvements to evaluate treatment efficacy. 
 
Results: All three trials used the FSFI questionnaire and reported a statistically significant (P < 
0.05) increase in mean change from baseline in sexual desire when using Tribulus terrestris. De 
Souza et al. and Vale et al. also reported a statistically significant (P < 0.05) increase in mean 
change from baseline of the placebo group of < 0.01 and 0.001, respectively. De Souza et al. and 
Vale et al. reported a statistically significant (P < 0.05) increase in sexual desire using QS-F results 
with a number needed to treat (NNT) of 20 and 4, respectively. 
 
Conclusion: Tribulus terrestris may safely and effectively improve sexual desire in women with 
HSDD; however, clear and concise methods and statistical analysis are needed to further 
investigate its full clinical potential. 
 
Key Words: Hypoactive sexual desire disorder, Tribulus terrestris, female sexual dysfunction 
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Introduction: 
 
Sexual dysfunction is a worldwide disease burden that affects many individuals, with 
significant accomplishments made thus far in the treatment, diagnosis, and pathophysiology of 
male erectile dysfunction, premature ejaculation, and testosterone deficiency syndrome. However, 
medical treatment and diagnosis of female sexual dysfunction to date still lag behind those of their 
male counterparts, with emphasis placed on difficulty understanding the female sexual response. 
The most prevalent sexual disorder affecting women is hypoactive sexual desire disorder (HSDD), 
defined as a persistent dysfunction in desire and fantasy to engage in sexual behaviors that leads 
to interpersonal distress not better explained by another condition.1 Distresses may include declines 
in self-esteem, mental health, and emotional role fulfillment. 
The sexual response is generally divided into four phases: desire, arousal, orgasm, and 
resolution. Unfortunately, this model does not hold consistently true for all women because of the 
multifactorial hormonal, neuronal, and psychosocial interactions that motivate female sexual 
response. The biology of desire is poorly understood in women, but it is hypothesized that HSDD 
is caused by some maladaptive neuronal process that precludes psychological priming for sex.2 
HSDD affects approximately 10% of all adult women, although the annual incidence and 
total healthcare cost of women seeking care for HSDD each year are currently unknown.3 
However, from a 1998-2006 data analysis we do know women with HSDD international 
classification of disease (ICD) diagnosis generally had higher healthcare expenditures compared 
to those undiagnosed.3 Historically, women perceive more barriers to accessing healthcare for 
sexual difficulties for a number of reasons, including cultural/societal norms, provider-based 
knowledge, and personal embarrassment.4 In a survey conducted in 2009 with 3,239 women, only 
34.5% had reported a sexual problem to their healthcare provider.4 HSDD is classified in the 
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Diagnostic and Statistical Manual of Mental Disorders (5th ed.; DSM-5; American Psychiatric 
Association, 2013) as part of Female Interest/Arousal Desire with diagnosis made on lack of 
interest and arousal; however, no set analysis criteria or algorithm guides diagnosis and treatment. 
This diagnostic ambiguity further promotes a lack of confidence in the healthcare system and 
compounds the under-recognized healthcare-seeking and diagnostic behavior of women with 
HSDD. 
Current treatment options for women with HSDD include both pharmacotherapy and 
psychotherapy. As of 2015, flibanserin was the only medication approved by the Food and Drug 
Administration (FDA) for treating HSDD in perimenopausal women. Some off-label 
pharmacological medications indicated for treatment are bupropion, sildenafil, buspirone, 
esterified estrogen/methyltesterone, and testosterone transdermal patches.1 Psychotherapy options 
include cognitive behavioral therapy, sensate focus, mindfulness training, and bibliotherapy.1 
While all of these treatments may have shown beneficial effects for women at one point, they have 
not been widely accepted in the clinical management of patients with HSDD. 
Herbal supplements have long been used in various cultures to treat and cure diseases. 
Tribulus terrestris is a plant native to Asia, Europe, and Africa and has long been endorsed 
culturally for its possible aphrodisiac properties. Recent studies propose some validity to its ability 
to mimic sex hormones for a natural option for women. The aim of this paper is to evaluate the 
efficacy of Tribulus terrestris in increasing sexual desire in adult women older than 18 years of 
age with HSDD by way of analyzing three double-blind randomized control trials. 
Objective: 
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The objective of this selective evidence-based medicine (EBM) review is to determine 
whether Tribulus terrestris is effective at increasing sexual desire in adult women suffering from 
HSDD. 
Methods: 
 
All three articles were researched using PubMed and were selected based on relevance to 
the clinical question and their patient-oriented outcomes. The key words used to identify literature 
included hypoactive sexual desire disorder, female sexual dysfunction, and Tribulus terrestris. 
Three double-blind randomized placebo-controlled clinical trials were used in this 
systematic review. All three studies required a population of adult women older than 18 years of 
age with reported diminished libido. Table 1 displays the key characteristics and demographics of 
the included studies. The intervention administered Tribulus terrestris orally to the experimental 
group and a visually equivalent placebo to the control group. The outcome measured was 
improvement in sexual desire. The statistics that were used and reported in all three studies were 
mean changes from baseline, P values, ANOVA test, Wilcoxon test, and McNemar test. 
Table 1: Demographics and Characteristics of Included Studies 
 
Study Type # Pts Age Inclusion 
Criteria 
Exclusion Criteria W/D Interventions 
Akhtari5 
(2014) 
Double Blind 
RCT 
67 36±7 
years 
Women of 
childbearing 
age, having 
normal breast 
exam, pelvic 
exam, negative 
pap smear, 
married and 
actively living 
with a partner, 
lack or loss of 
libido causing 
distress 
Lack of steady 
sexual partner, 
serious medical 
condition, major 
depression disorder 
or other psychiatric 
disorders, history of 
genital tract or 
breast cancers, 
menopause, 
pregnancy, 
husband’s sexual 
problems and active 
plans for divorce 
7 Tribulus 
terrestris extract 
7.5mg/day 
De Souza 
KZ6 
(2016) 
Prospective 
double-blind 
RCT 
45 43-65 
years 
Age between 
1-10 yrs since 
last menstrual 
period, FSH 
Used hormone or 
drugs within 
previous year, 
smokers, had HTN, 
9 Tribulus 
terrestris 250 mg 
TID orally 
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    level > 30, 
estradiol level 
< 40, body 
mass index 
less than 28 
collagenosis, 
unbalanced 
endocrine system, 
pulmonary, renal, 
hepatic, vascular, 
thromboembolic 
disease, history of 
endometrial cancer, 
MI, oophorectomy, 
partner with sexual 
problems, 
interpersonal 
relationship 
problems 
  
Vale7 
(2017) 
Double blind 
RCT 
64 18-44 
years 
Stable 
relationship 
for 2 yrs, 
regular 
menstrual 
cycles, 
diminished 
libido 
Pregnant, on 
hormonal 
contraception, 
regular/medications, 
clinically depressed, 
had HTN, 
collagenosis, 
unbalanced 
endocrine system, 
pulmonary, renal, 
hepatic, vascular, 
thromboembolic 
disease, history of 
endometrial cancer, 
MI, partner with 
sexual problems, 
interpersonal 
relationship 
problems 
24 Tribulus 
terrestris 250 mg 
TID orally 
 
 
Outcomes Measured: 
 
All three articles used the Female Sexual Function Index (FSFI) questionnaire to assess the 
efficacy of Tribulus terrestris therapy in improving sexual desire. The FSFI questionnaire assesses 
6 domains of female sexual function: desire, arousal, lubrication, orgasm, satisfaction, and pain. 
Vale et al. and de Souza et al. used an additional questionnaire, the sexual quotient female (QS-F) 
questionnaire, which includes 5 domains: desire, arousal/lubrication, orgasm, pain, and 
satisfaction. Both surveys use Likert-type response formats and are scored from 0 to 5. Low scores 
from both questionnaires indicate severe female sexual dysfunction. 
Results: 
Bell, Tribulus terrestris and HSDD, 5 
 
 
Akhatri et al. selected 67 adult women of whom 33 were randomly assigned to the 
experimental group and 34 to the control group. Of the 67 women, a total of 7 discontinued the 
trial because of noncompliance, loss to follow up, or withdrawn consent.5 The randomized study 
was conducted in two medical centers in the Tehran Province of Iran. De Souza et al. selected 45 
women for their study from which 9 were excluded: 3 withdrew because of personal reasons and 
6 as a result of adverse side effects from taking the medication. This study was conducted in the 
Clinic of Sexology of the Department of Gynecology and Obstetrics in Brazil. Vale et al. selected 
64 women from which 24 were excluded from the study because of noncompliance or loss to 
follow up. This study was conducted at the Universidade Federal de Minas Gerais in Brazil. None 
of the excluded patients were used in the final analysis across all trials. Figure 1 illustrates subject 
group allocations, exclusions, and completions across all 3 trials. 
Figure 1: Flow chart indicating subject group allocations, exclusions and completions across all 3 trials 
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All three trials used the FSFI questionnaire and reported a statistically significant (P < 
0.05) increase in mean change from baseline in sexual desire when using Tribulus terrestris. De 
Souza et al. and Vale et al. also reported a statistically significant (P < 0.05) increase in mean 
change from baseline of the placebo group of <0.01 and 0.001 respectively. The results are 
illustrated in Table 2. Data from these trials using FSFI as an outcome measure were reported as 
continuous data that could not be converted to dichotomous form to further evaluate efficacy of 
treatment. Vale et al. and de Souza et al. noted no statistically significant difference in the FSFI 
scores between groups before treatment, with P values > 0.1 validating homogeneity. Akharti et 
al. did not report on any statistical significance between groups on the FSFI before treatment. 
Table 2: Efficacy of Tribulus terrestris in improving sexual desire using FSFI within groups 
Study Tribulus terrestris 
mean change from 
baseline 
Placebo Mean 
change from 
baseline 
P value* P value** 
Akhtari et al. .84 .2 < 0.0001+ N/A 
De Souza et al. 1.6 1.2 <0.01 <0.01 
Vale et al. 1.59 1.14 <0.001 0.001 
*p value of Tribulus terrestris pre and post treatment with no variance accountability 
**p value of placebo pre and post treatment with no variance accountability 
+variance between the two groups are accounted 
 
Using QS-F, both de Souza et al. and Vale et al. reported a statistically significant (P < 
0.05) increase in sexual desire. Vale et al. reported a QS-F score in the desire domain that 
showed 70% of women who were taking Tribulus terrestris compared to 65% of women taking 
placebo felt an improvement in desire, for a number needed to treat (NNT) of 20.7 A NNT of 20 
means that for every 20 women treated with Tribulus terrestris, one more person will achieve the 
desired outcome compared to those taking the placebo. De Souza et al. trial reported a QS-F 
score in the desire domain that showed 75% of women who were taking Tribulus terrestris 
compared to 50% of women taking placebo felt an improvement in desire, for a NNT of 4.6 The 
results for QS-F are shown in Table 3. 
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Table 3: Efficacy of Tribulus terrestris in the treatment of HSDD using QS-F 
Study CER EER RRI ARI NNT P value 
Vale et al 0.65 0.70 0.08 0.05 20 <0.01 
De Souz et al 0.50 0.75 0.50 0.25 4 0.01 
 
 
One adverse effect of abdominal cramping was reported in the Akhatri et al. study; 
however, the group was not specified. Vale et al. did not report any side effects using the drug or 
placebo within the respective groups. De Souza et al. reported nausea as a side effect, with 6 
women withdrawing, 3 from the placebo group and 3 from the experimental group. Compliance 
of the participants was not noted in the studies conducted by Vale et al. and de Souza et al. over 
the 120-day duration of the trials.6,7 The study conducted by Ahkatri et al. reported that 
participants were followed for 2 consecutive months with 3 in-person visits throughout the 
length of the 4-week study. 
 
Discussion 
 
Flibanserin is the only drug approved by the FDA for treating HSDD for perimenopausal 
women; therefore, in the absence of treatment options, homeopathic products offer alternative 
therapy. Since flibanserin was approved only for perimenopausal women in the United States, its 
application to all women is limited, and some associated side effects, such as somnolence, 
dizziness, and insomnia, exist. All of the noted side effects are significant, as they could interfere 
with its intended use of initiating and increasing sexually satisfying events. 
Using three double-blind randomized controlled trials, this selective systematic analysis 
reviewed the safety and efficacy of Tribulus terrestris in improving the sexual desire in women 
with HSDD older than 18 years of age. Exclusion criteria were exhaustive and included both 
medical and psychological conditions, medications, and other sexual dysfunctions in addition   to 
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HSDD. All three trials using the FSFI and QS-F questionnaires showed that in these women with 
HSDD, taking Tribulus terrestris was associated with a statistically significant increase in sexual 
desire. While the FSFI is a well-accepted questionnaire vetted to assess female dysfunction and is 
used in numerous trials, including those that led to the FDA approval of flibanserin, QS-F is not. 
QS-F was developed to specifically assess female sexual dysfunction in Brazilian women. 
Therefore, the extent to which this questionnaire can be used in the United States as a treatment 
outcome would need further evaluation. Also, no P values were reported in the Vale et al. and de 
Souza et al. studies between the treatment and placebo groups before and after treatment that 
adjusted for variance to further solidify the statistical significance of the treatment intervention. 
All three studies varied in the population studied, manufacturers used, compliance 
surveillance, length of drug administration, and intervention formulations. All studies were 
conducted outside the United States in countries with different attitudes toward sexual health. 
Akharti et al. noted that Iranian women tend to be more reserved in their sexual beliefs because of 
their conservative culture, leading to over- or underestimations in sexual desire.5 Akhatri et al. 
used a syrup formulation of Tribulus terrestris over 4 weeks while Vale et al. and de Souza et al. 
used tablets and assessed over 120 days. Therefore, from the three studies, therapeutic treatment 
lengths and formulations were not evaluated and may have contributed to the variations in 
outcomes although all studies showed benefits. 
The FDA does not regulate alternative products, such as herbal or nutritional supplements, 
thus limiting the number of available studies undergoing rigorous scientific compliance when 
measuring objective patient outcomes. Moreover, the exact mechanism of the effect of Tribulus 
terrestris on increasing sexual desire is not well understood, creating another hurdle in the 
number of clinical trials available. From the lower NNT of 4 obtained in the De Souza et al. 
study compared to the Vale et al. study of 20 some inferences can be made on the possible effect 
of Tribulus terrestris on hormones since the two study groups mainly differed in post and 
premenopausal women. Postmenopausal women naturally undergo significant hormonal  
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changes. The worldwide use of herbs is increasing; therefore, women will have no problems 
obtaining this supplement from the market. Healthcare providers will inevitably encounter 
women in the primary-care or gynecological setting seeking advice on herbal supplements for 
HSDD.  
Conclusion: 
Tribulus terrestris may safely and effectively improve sexual desire in women with HSDD; 
however, clear and concise methods and statistical analysis are needed to further investigate its 
full clinical potential. The studies conducted by Vale et al and de Souza et al could have taken data 
a step further to assess the true statistical significance of Tribulus terrestris intervention before and 
after treatment compared to the placebo group after matching for effective variance. No serious or 
life-threatening adverse reactions were reported. However, research is needed in the United States 
with clearly defined and vetted patient outcome measurements appropriate for the culture of the 
population. Studies using diary documentations for compliance and sexually satisfying events as 
part of the measured outcome would also add great value to further research methods. Tribulus 
terrestris production quality standardization is another area that if included in future studies will 
help  to increase confidence in its efficacy.  
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